MedTrace Logo

Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients

NCT02456051 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2017-11-20

No results posted yet for this study

Summary

Pancreatic Cancer is a leading cause of cancer-related death. To date, only one fifth of patients at diagnosis is presented resectable because the diagnosis is often delayed making the 5-year survival of this disease globally less than 5%. An early diagnosis in these patients is currently not possible given the economic disadvantages of a population-wide screening. New evidences identify patients with new-onset diabetes as a subgroup of patients at high risk of developing this disease (RR 5:38). In a subset of these patients a mediator secreted by the tumor, the Adrenomedullin, could be responsible for the onset of diabetes. Our goal is therefore to assess the different impact of Pancreatic Cancer depending on Adrenomedullin values in patients with newly diagnosed diabetes mellitus.

Conditions

  • Diabetes Mellitus, Adult-Onset
  • Diabetes Complications
  • Carcinoma, Pancreatic Ductal
  • Pancreatic Neoplasm

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Laura Antolino, MD · Università Sapienza di Roma

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456051 on ClinicalTrials.gov